Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.05.5335 on September 11 2006

Journal of Clinical Oncology, Vol 24, No 29 (October 10), 2006: pp. 4721-4730
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemunaitis, J.
Right arrow Articles by Fakhrai, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemunaitis, J.
Right arrow Articles by Fakhrai, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul O. Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, Padmasini Kumar, Beena Pappen, Cody Hamilton, Edward DeVol, Phillip B. Maples, Lily Liu, Terry Chamberlin, Daniel L. Shawler, Habib Fakhrai

From the Mary Crowley Medical Research Center/Texas Oncology Professional Association; Baylor Sammons Cancer Center, Baylor University Medical Center; Murex Pharmaceutical Inc; Institute for Health Care Research and Improvement, Baylor Health Care System, Dallas, TX; Hoag Cancer Center, Newport Beach; NovaRx Corporation, San Diego, CA; and Louisiana State University, New Orleans, LA

Address reprint requests to John Nemunaitis, MD, 1717 Main St, 60th Floor, Dallas, TX 75201; e-mail: jnemunaitis{at}mcmrc.com

PURPOSE: Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition.

PATIENTS AND METHODS: We performed a randomized, dose-variable, phase II trial involving stages II, IIIA, IIIB, and IV non–small-cell lung cancer patients. Each patient received one of three doses (1.25, 2.5, or 5.0 x 107 cells/injection) of belagenpumatucel-L on a monthly or every other month schedule to a maximum of 16 injections. Immune function, safety, and anticancer activity were monitored.

RESULTS: Seventy-five patients (two stage II, 12 stage IIIA, 15 stage IIIB, and 46 stage IV patients) received a total of 550 vaccinations. No significant adverse events were observed. A dose-related survival difference was demonstrated in patients who received ≥ 2.5 x 107 cells/injection (P = .0069). Focusing on the 61 late-stage (IIIB and IV) assessable patients, a 15% partial response rate was achieved. The estimated probabilities of surviving 1 and 2 years were 68% and 52%, respectively for the higher dose groups combined and 39% and 20%, respectively, for the low-dose group. Immune function was explored in the 61 advanced-stage (IIIB and IV) patients. Increased cytokine production (at week 12 compared with patients with progressive disease) was observed among clinical responders (interferon gamma, P = .006; interleukin [IL] -6, P = .004; IL-4, P = .007), who also displayed an elevated antibody-mediated response to vaccine HLAs (P = .014). Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L showed a correlation trend (P = .086) with clinical responsiveness in patients achieving stable disease or better.

CONCLUSION: Belagenpumatucel-L is well tolerated, and the survival advantage justifies further phase III evaluation.

published online ahead of print at www.jco.org on September 11, 2006.

Supported in part by Small Business Innovative Research Grant No. 1 R44 CA96025 (H.F.).

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
U. Petrausch, S. M. Jensen, C. Twitty, C. H. Poehlein, D. P. Haley, E. B. Walker, and B. A. Fox
Disruption of TGF-{beta} Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity
J. Immunol., September 15, 2009; 183(6): 3682 - 3689.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. Gridelli, A. Rossi, P. Maione, M. L. Ferrara, V. Castaldo, and P. C. Sacco
Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy
Oncologist, September 1, 2009; 14(9): 909 - 920.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
G. K. Dy and A. A. Adjei
Emerging Therapeutic Targets in Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 218 - 223.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
E. A. Hirschowitz and J. R. Yannelli
Immunotherapy for Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 224 - 232.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al.
Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy
Cancer Res., December 15, 2008; 68(24): 10247 - 10256.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al.
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 20, 2008; 26(27): 4418 - 4425.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Wallraven, J. J. Nemunaitis, and P. B. Maples
Compassionate Approval Process for Experimental Gene-Based Products
J. Clin. Oncol., April 10, 2008; 26(11): 1899 - 1900.
[Full Text] [PDF]


Home page
JCOHome page
J. J. Nemunaitis
Are Vaccines Making a Comeback in Non-Small-Cell Lung Cancer?
J. Clin. Oncol., March 20, 2008; 26(9): 1402 - 1403.
[Full Text] [PDF]


Home page
JCOHome page
E. N. Vinageras, A. de la Torre, M. O. Rodriguez, M. C. Ferrer, I. Bravo, M. M. del Pino, D. A. Abreu, S. A. Brooks, R. Rives, C. del Castillo Carrillo, et al.
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 20, 2008; 26(9): 1452 - 1458.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock
Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling
Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online